Tonix Pharmaceuticals Holding (TNXP) Accounts Payables (2010 - 2026)

Tonix Pharmaceuticals Holding's Accounts Payables history runs 17 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 130.12% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $9.6 million, a 130.12% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 78.49% from the prior year.
• Accounts Payables climbed to $9.6 million in Q1 2026 per TNXP's latest filing, from $8.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $10.4 million in Q2 2024 and bottomed at $3.8 million in Q4 2023.
• The 5-year median for Accounts Payables is $7.8 million (2023), against an average of $7.2 million.
• Across the five-year window, Accounts Payables surged 228.68% in 2022 and sank 53.12% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $8.1 million in 2022, then sank by 53.12% to $3.8 million in 2023, then rose by 20.2% to $4.5 million in 2024, then surged by 78.49% to $8.1 million in 2025, then gained by 18.92% to $9.6 million in 2026.
• Per Business Quant, the three latest TNXP Accounts Payables figures stand at $9.6 million (Q1 2026), $8.1 million (Q4 2025), and $8.5 million (Q3 2025).